Updated: Mar 13
This article is brought to you by the new Cannabis Commerce + Chemistry Podcast.
Welcome to Cannabis Conclusions, a unique educational series from Higher Learning LV that is targeted at hemp and cannabis industry professionals. This series provides readers with the conclusion section from important modern peer-reviewed research studies.
A January 2022 study entitled "A Narrative Review of Molecular Mechanism and Therapeutic Effect of Cannabidiol (CBD)" that was published in the journal Basic & Clinical Pharmacology and Toxicology explored "the molecular mechanisms of action of the therapeutic effects of CBD within different disease contexts," with a focus on "diseases in which there are human experiments or clinical studies with CBD."
This conclusion section is provided verbatim, with the exception of the addition of paragraph breaks to increase readability and comfort level.
"In this review, we summarized the molecular mechanisms and clinical experience in support of CBD as a potential therapeutic compound for various diseases. Among them, CBD has been approved for the treatment of seizures associated with LGS and DS, as well as TSC in the United States and EU. Further clinical and mechanistic studies are necessary to fully explore the therapeutic potential of CBD in various diseases.
"More well-designed, randomized, placebo-controlled, double-blind clinical trials with diverse populations are needed."
"Although CBD exhibited promising therapeutic benefits for some diseases in initial clinical trials, a large percentage of clinical data comes from case studies or open-label trials, which must be interpreted cautiously due to the absence of placebo control, leading to possible biased effects associated with CBD treatment.
"Therefore, more well-designed, randomized, placebo-controlled, double-blind clinical trials with diverse populations are needed to evaluate and support the therapeutic efficacy and utility of CBD for multiple disease states."
Are you a cannabis industry professional? Check out Higher Learning LV's Deep Dive Subscription that features dozens of long-form articles based on the latest peer-reviewed scientific research. Priced to accommodate personal and enterprise training budgets.